"Patient-reported outcomes in futibatinib-treated intrahepatic cholangiocarcinoma patients with fgfr2 fusions/rearrangements: results from the foenix-CCA2 study "
Bridgewater, JA Hollebecque, A. Furuse, J Goyal, L Meric-Bernstam, F Epstein, R. S. Morlock, R. Salimi, T. Wacheck, V. Liu, M
Bridgewater, JA
Hollebecque, A.
Furuse, J
Goyal, L
Meric-Bernstam, F
Epstein, R. S.
Morlock, R.
Salimi, T.
Wacheck, V.
Liu, M
Citations
Altmetric:
Abstract
We report patient-reported outcomes (PROs) results from the pivotal phase 2 trial FOENIX-CCA2 (NCT02052778). FOENIX-CCA2 evaluated futibatinib, an irreversible FGFR1–4 inhibitor, among intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements. Futibatinib demonstrated a confirmed objective response rate of 41.7%; adverse events were manageable. PROs were a prespecified secondary objective of the study.
Affiliation
Description
Date
2022
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Bridgewater, J A, Hollebecque, A, Furuse, J, Goyal, L, Meric-Bernstam, F, Epstein, R S, Morlock, R, Salimi, T, Wacheck, V, Liu, M, Benhadji, K, Valle, Juan W. "Patient-reported outcomes in futibatinib-treated intrahepatic cholangiocarcinoma patients with fgfr2 fusions/rearrangements: results from the foenix-CCA2 study. Value in Health . 2022